β受体阻滞剂与老年养老院居民急性心肌梗死后功能结局、死亡及再住院的关联
该队列研究利用2007年5月1日至2010年3月31日美国国家最低数据集2.0版及Medicare A/D部分数据,纳入65岁以上长期养老院居民急性心梗后新使用β受体阻滞剂者与非使用者,采用倾向评分匹配比较90天内功能下降、死亡和再住院。匹配队列共10992人(平均年龄84岁),β受体阻滞剂使用者功能下降风险更高(OR 1.14,95%CI 1.02-1.28;NNH 52),但死亡风险更低(HR 0.74,95%CI 0.67-0.83),再住院率相似(HR 1.06,95%CI 0.98-1.14)。中度或重度认知障碍者(OR 1.34)及严重功能依赖者(OR 1.32)功能下降风险尤其显著,而认知完好或轻度痴呆者及功能独立最好和中间三分位者未见显著功能下降。各亚组死亡获益相似。
要点
- 养老院老年居民心梗后新用β受体阻滞剂90天死亡风险降低:HR 0.74(95%CI 0.67-0.83),各亚组获益相似。
- 总体功能下降风险增加:OR 1.14(95%CI 1.02-1.28),Number Needed to Harm 52(95%CI 32-141)。
- 中度或重度认知障碍者功能下降OR 1.34(95%CI 1.11-1.61),严重功能依赖者OR 1.32(95%CI 1.10-1.59)。
- 认知完好或轻度痴呆者功能下降无显著增加:OR 1.03(95%CI 0.89-1.20),交互作用P=0.03。
- 再住院率相似:HR 1.06(95%CI 0.98-1.14),未达统计学显著。
适用人群与场景
- 65岁及以上长期养老院居民,2007年5月1日至2010年3月31日期间发生急性心肌梗死并住院。
- 排除急性心梗前已使用β受体阻滞剂者。
研究设计与关键结果
- 研究类型:队列研究,使用国家最低数据集2.0版及Medicare A/D部分数据,倾向评分匹配比较新使用β受体阻滞剂者与非使用者。
- 初始队列15720人(女性11140人[70.9%],男性4580人[29.1%],平均年龄83岁[SD 8]),其中新使用者8953人,非使用者6767人。
- 倾向评分匹配队列:新使用β受体阻滞剂者5496人与等量非使用者,共10992人(女性7788人[70.9%],男性3204人[29.1%],平均年龄84岁[SD 8])。
- 主要结局(90天内):β受体阻滞剂使用者较非使用者功能下降风险更高,OR 1.14(95%CI 1.02-1.28),NNH 52(95%CI 32-141)。
- 死亡:β受体阻滞剂使用者死亡风险更低,HR 0.74(95%CI 0.67-0.83)。
- 再住院:β受体阻滞剂使用者再住院率相似,HR 1.06(95%CI 0.98-1.14)。
- 亚组:中度或重度认知障碍者功能下降OR 1.34(95%CI 1.11-1.61),严重功能依赖者OR 1.32(95%CI 1.10-1.59)。
- 认知完好或轻度痴呆者功能下降OR 1.03(95%CI 0.89-1.20),交互作用P=0.03;功能独立最好三分位OR 0.99(95%CI 0.77-1.26),中间三分位OR 1.05(95%CI 0.86-1.27),交互作用P=0.06。
证据类型、等级与局限
- 证据类型:队列研究(倾向评分匹配分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对认知完好或轻度痴呆、功能相对保留的养老院老年心梗后患者,β受体阻滞剂与死亡降低相关且未观察到显著功能下降。
- 对中度或重度认知障碍或严重功能依赖的养老院老年心梗后患者,β受体阻滞剂与功能下降风险增加相关,同时死亡获益在各亚组相似。
- 再住院率在β受体阻滞剂使用者与非使用者间无显著差异(HR 1.06,95%CI 0.98-1.14)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Although β-blockers are a mainstay of treatment after acute myocardial infarction (AMI), these medications are commonly not prescribed for older nursing home residents after AMI, in part owing to concerns about potential functional harms and uncertainty of benefit.
OBJECTIVE: To study the association of β-blockers after AMI with functional decline, mortality, and rehospitalization among long-stay nursing home residents 65 years or older.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study of nursing home residents with AMI from May 1, 2007, to March 31, 2010, used national data from the Minimum Data Set, version 2.0, and Medicare Parts A and D. Individuals with β-blocker use before AMI were excluded. Propensity score-based methods were used to compare outcomes in people who did vs did not initiate β-blocker therapy after AMI hospitalization.
MAIN OUTCOMES AND MEASURES: Functional decline, death, and rehospitalization in the first 90 days after AMI. Functional status was measured using the Morris scale of independence in activities of daily living.
RESULTS: The initial cohort of 15 720 patients (11 140 women [70.9%] and 4580 men [29.1%]; mean [SD] age, 83 [8] years) included 8953 new β-blocker users and 6767 nonusers. The propensity-matched cohort included 5496 new users of β-blockers and an equal number of nonusers for a total cohort of 10 992 participants (7788 women [70.9%]; 3204 men [29.1%]; mean [SD] age, 84 [8] years). Users of β-blockers were more likely than nonusers to experience functional decline (odds ratio [OR], 1.14; 95% CI, 1.02-1.28), with a number needed to harm of 52 (95% CI, 32-141). Conversely, β-blocker users were less likely than nonusers to die (hazard ratio [HR], 0.74; 95% CI, 0.67-0.83) and had similar rates of rehospitalization (HR, 1.06; 95% CI, 0.98-1.14). Nursing home residents with moderate or severe cognitive impairment or severe functional dependency were particularly likely to experience functional decline from β-blockers (OR, 1.34; 95% CI, 1.11-1.61 and OR, 1.32; 95% CI, 1.10-1.59, respectively). In contrast, little evidence of functional decline due to β-blockers was found in participants with intact cognition or mild dementia (OR, 1.03; 95% CI, 0.89-1.20; P = .03 for effect modification) or in those in the best (OR, 0.99; 95% CI, 0.77-1.26) and intermediate (OR, 1.05; 95% CI, 0.86-1.27) tertiles of functional independence (P = .06 for effect modification). Mortality benefits of β-blockers were similar across all subgroups.
CONCLUSIONS AND RELEVANCE: Use of β-blockers after AMI is associated with functional decline in older nursing home residents with substantial cognitive or functional impairment, but not in those with relatively preserved mental and functional abilities. Use of β-blockers yielded a considerable mortality benefit in all groups.
参考来源
- Steinman MA, Zullo AR, Lee Y, et al. Association of β-Blockers With Functional Outcomes, Death, and Rehospitalization in Older Nursing Home Residents After Acute Myocardial Infarction. JAMA Intern Med. 2017. PMID: 27942713. doi:10.1001/jamainternmed.2016.7701
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。